Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2212-2220

  Hwang, Jessica P ^a   Somerfield, Mark R ^c   Alston Johnson, Devena E ^d   Cryer, Donna R ^e   Feld, Jordan J ^f   Kramer, Barnett S ^g   Sabichi, Anita L ^b   Wong, Sandra L ^h   Artz, Andrew S ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d Upstate Urology Associates   (United States)

^e Global Liver Institute   (United States)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; VIRUS DNA; ANTINEOPLASTIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER PATIENT; CANCER THERAPY; CANCER TRANSPLANTATION; CONSENSUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; PATIENT MONITORING; PRIORITY JOURNAL; RISK REDUCTION; SCREENING; SEROLOGY; VIRUS REACTIVATION; HEPATITIS B, CHRONIC; MASS SCREENING; MEDICAL SOCIETY; NEOPLASMS; ONCOLOGY; PRACTICE GUIDELINE; PROCEDURES; RISK FACTOR; STANDARDS; UNITED STATES; VIRUS ACTIVATION;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B, CHRONIC; HUMANS; MASS SCREENING; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SOCIETIES, MEDICAL; UNITED STATES; VIRUS ACTIVATION;

EID: 84937125222     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.3745     Document Type: Article

References (43)

1. Artz AS, Somerfield MR, Feld JJ, et al: American Society of Clinical Oncology provisional clinical opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199-3202, 2010
2. Hwang JP, Fisch MJ, Zhang H, et al: Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 8:e32-e39, 2012
3. Hwang JP, Fisch MJ, Lok AS, et al: Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 13:534, 2013
4. US Department of Health and Human Services: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis: Updated, 2014-2016. http://aids.gov/pdf/viral-hepatitis-action-plan.pdf
5. US Food and Drug Administration: FDA drug safety communication: Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anticancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). http://www.fda.gov/Drugs/DrugSafety/ucm366406.htm
6. US Food and Drug Administration: Label information for rituximab. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103705s5414lbl.pdf
7. US Food and Drug Administration: Label information for ofatumumab. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125326s059lbl.pdf
8. Neuss MN, Desch CE, McNiff KK, et al: A process for measuring the quality of cancer care: The Quality Oncology Practice Initiative. J Clin Oncol 23:6233-6239, 2005
9. Huang YH, Hsiao LT, Hong YC, et al: Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31:2765-2772, 2013
10. Lok ASF, McMahon BJ: AASLD practice guideline update: Chronic hepatitis B: Update 2009. http://www.aasld.org/sites/default/files/guideline-documents/ChronicHepatitisB2009.pdf
11. Weinbaum CM, Williams I, Mast EE, et al: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1-20, 2008
12. McNamara C, Davies J, Dyer M, et al: Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 156:446-467, 2012
13. Dreyling M, Ghielmini M, Marcus R, et al: Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii76-iii82, 2014 (suppl 3)
14. Zelenetz AD, Gordon LI, Wierda WG, et al: Non-Hodgkin's lymphomas, version 4.2014. J Nat Compr Canc Netw 12:1282-1303, 2014
15. National Comprehensive Cancer Network: Prevention and treatment of cancer-related infections (version 2.2014). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
16. Reddy KR, Beavers KL, Hammond SP, et al: American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215-219, 2015
17. Hay AE, Meyer RM: Hepatitis B, rituximab, screening, and prophylaxis: Effectiveness and cost effectiveness. J Clin Oncol 30:3155-3157, 2012
18. National Institute for Health and Care Excellence: Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people, and adults. http://www.nice.org.uk/guidance/CG165
19. American Society of Clinical Oncology: ASCO provisional clinical opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. http://www.instituteforquality.org/asco-provisional-clinicalopinion-chronic-hepatitis-b-virus-infection-screening-patients-receiving
20. US Food and Drug Administration: Label information for obinutuzumab. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125486s000lbl.pdf
21. Trépo C, Chan HL, Lok A: Hepatitis B virus infection. Lancet 384:2053-2063, 2014
22. Hwang JP, Lok AS: Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11:209-219, 2014
23. Loomba R, Rowley A, Wesley R, et al: Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528, 2008
24. Pawlotsky JM: Virology of hepatitis B and C viruses and antiviral targets. J Hepatol 44:S10-S13, 2006 (suppl)
25. Rehermann B, Ferrari C, Pasquinelli C, et al: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108, 1996
26. Abbott Prism: Hepatitis B virus core antigen (G1-0036/R12). November 2012
27. Abbott Prism: Antibody to Hepatitis B surface antigen (GL-0023/R12). November 2012
28. Hammond SP, Swaminathan S, Bensinger WI, et al: Hepatitis B virus screening and potential reactivation in patients undergoing treatment for cancer. J Natl Compr Canc Netw 12:1655-1657, 2014
29. LeFevre ML: Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 161:58-66, 2014
30. Chou R, Dana T, Bougatsos C, et al: Screening for hepatitis B virus infection in adolescents and adults: A systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 161:31-45, 2014
31. Reference deleted
32. Yeo W, Zee B, Zhong S, et al: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306-1311, 2004
33. Perrillo RP, Gish R, Falck-Ytter YT: American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B reactivation during immunosuppressive drug therapy. Gastroenterology 148:221.e3-244.e3, 2015
34. Hsu C, Hsiung CA, Su IJ, et al: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 47:844-853, 2008
35. Lau GK, Yiu HH, Fong DY, et al: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749, 2003
36. Zurawska U, Hicks LK, Woo G, et al: Hepatitis B virus screening before chemotherapy for lymphoma: A cost-effectiveness analysis. J Clin Oncol 30:3167-3173, 2012
37. Day FL, Karnon J, Rischin D: Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29:3270-3277, 2011
38. Yeo W, Chan TC, Leung NW, et al: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009
39. Hsu C, Tsou HH, Lin SJ, et al: Chemotherapyinduced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology 59:2092-2100, 2014
40. Seto WK, Chan TS, Hwang YY, et al: Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: A prospective study. J Clin Oncol 32:3736-3743, 2014
41. Huang H, Li X, Zhu J, et al: Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. JAMA 312:2521-2530, 2014
42. Abramson JS, Chung RT: Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. JAMA 312:2505-2507, 2014
43. Keam B, Lee JH, Im SA, et al: Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw 9:465-477, 2011